NCT05549934View on ClinicalTrials.gov

Ritlecitinib for Cicatricial Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

March 20, 2025

Study Completion Date

March 20, 2025

Conditions
Cicatricial Alopecia
Interventions
DRUG

PF-06651600

tablets containing active drug (a combined JAK3/TEC inhibitor)

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Emma Guttman

OTHER

NCT05549934 - Ritlecitinib for Cicatricial Alopecia | Biotech Hunter | Biotech Hunter